Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | ||
Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Waldenström’s macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Chronic lymphocytic leukemia /small lymphocytic lymphoma. | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete |